NCT03589222
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03589222
Title SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors PETHEMA Foundation
Indications
Therapies
Age Groups: adult | senior
Covered Countries ESP

Facility Status City State Zip Country Details
Hospital Germans Trials i Pujol Badalona Spain Details
Hospital Clinic de Barcelona Barcelona Spain Details
Hospital ICO de Girona Girona Spain Details
Hospital ICO de L'hospitalet L'Hospitalet de Llobregat Spain Details
Hospital 12 de Octubre Madrid Spain Details
Hospital Clinico de Madrid Madrid Spain Details
Hospital Morales Meseguer Murcia Spain Details
Hospital Central de Asturias Oviedo Spain Details
Clinica Universitaria de Navarra Pamplona Spain Details
Hospital Clinico Universitario de Salamanca Salamanca Spain Details
Hospital Universitario de Donostia San Sebastián Spain Details
Hospital Universitario de Canarias Santa Cruz de Tenerife Spain Details
Hospital Universitario de Santiago Santiago de Compostela Spain Details
Hospital Virgen del Rocio Seville Spain Details
Hospital Dr Peset Valencia Spain Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field